Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Just relistened to 18th IASLC WCLC: Poziotinib Update Conference Call from Oct 18th w Dr. Heymach of MDACC. For some reason it was fun listening; it just puts a smile to your face:). Several times when Dr. Heymach mentioned/discussed the HER2 Exon 20 mutation and patients he stated

we'll report these results in the near future

Well the 2018 AACR on April 17th seems to be the near future and the title of the abstract Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing seems to address this (bigtime).

Results on HER2 mutation should be as good or better than the EGFR mutation. Ed White of FBR Capital Markets asked Dr. Heymach

(paraphrasing) Q Any expectation to see any difference between responses to HER2 and EGFR

Ans - the pockets are very similar and the other thing is the data shows mutations further along the loop are more resistant. Now the HER2 insertions are in more sensitive regions so one would predict they are very sensitive

Added clarification by me - by being more sensitive, the mutation is more susceptible to pozi.